Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Korean Circ J. 2015 Jan;45(1):51-8. doi: 10.4070/kcj.2015.45.1.51. Epub 2015 Jan 26.
Cardiovascular complications are the leading cause of morbidity and mortality in childhood cancer survivors. Hematopoietic stem cell transplantation (HSCT) is a curable therapy for pediatric cancer. However, changes in cardiac function in children after HSCT are not well known. We assessed left ventricular (LV) function in children after HSCT using speckle tracking echocardiography (STE).
Forty consecutive patients with median age of 11.9 years (range, 1.5-16 years) who received HSCT for acute leukemia and had comprehensive echocardiography before and after (median 9.2 month) HSCT were included in this study. The LV function parameters including conventional tissue Doppler imaging (TDI) and STE data were collected from pre- and post-HSCT echocardiography. These data were compared to those of 39 age-matched normal controls.
Compared to normal controls, post HSCT patients had similar (p=0.06) LV ejection fraction. However, the following three LV function parameters were significantly decreased in post HSCT patients: rate-corrected velocity of circumferential fiber shortening (p=0.04), mitral inflow E velocity (p<0.001), and mitral septal annular E' velocity (p=0.03). The following four STE parameters were also significantly decreased in post HSCT patients: LV global circumferential systolic strain (p<0.01), strain rate (SR, p=0.01), circumferential diastolic SR (p<0.01), and longitudinal diastolic SR (p<0.001). There was no significant change in TDI or STE parameters after HSCT compared to pre-HSCT. Patients with anthracycline cumulative dose >400 mg/m(2) showed significantly (p<0.05) lower circumferential systolic strain and circumferential diastolic SR.
Subclinical cardiac dysfunction is evident in children after HSCT. It might be associated with pre-HSCT anthracycline exposure with little effect of conditioning regimens. Serial monitoring of cardiac function is mandatory for all children following HSCT.
心血管并发症是儿童癌症幸存者发病率和死亡率的主要原因。造血干细胞移植(HSCT)是儿科癌症的一种可治愈疗法。然而,HSCT 后儿童心脏功能的变化尚不清楚。我们使用斑点追踪超声心动图(STE)评估 HSCT 后儿童的左心室(LV)功能。
本研究纳入了 40 例连续接受 HSCT 治疗急性白血病的患者,中位年龄为 11.9 岁(范围为 1.5-16 岁),在 HSCT 前后(中位时间为 9.2 个月)进行了全面的超声心动图检查。从 HSCT 前后的超声心动图中收集了包括传统组织多普勒成像(TDI)和 STE 数据在内的 LV 功能参数。将这些数据与 39 名年龄匹配的正常对照进行比较。
与正常对照组相比,HSCT 后患者的 LV 射血分数相似(p=0.06)。然而,HSCT 后患者的以下三个 LV 功能参数显著降低:校正后的圆周纤维缩短速度(p=0.04)、二尖瓣血流 E 速度(p<0.001)和二尖瓣间隔环 E'速度(p=0.03)。HSCT 后患者的以下四个 STE 参数也显著降低:LV 整体圆周收缩应变(p<0.01)、应变率(SR,p=0.01)、圆周舒张 SR(p<0.01)和纵向舒张 SR(p<0.001)。HSCT 后与 HSCT 前相比,TDI 或 STE 参数没有明显变化。累积蒽环类药物剂量>400mg/m2的患者圆周收缩应变和圆周舒张 SR 显著降低(p<0.05)。
HSCT 后儿童存在亚临床心脏功能障碍。这可能与 HSCT 前蒽环类药物暴露有关,而与预处理方案关系不大。所有接受 HSCT 的儿童都需要进行心脏功能的连续监测。